Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors
Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection
IND-enabling studies underway, with Phase I study initiation expected in 2Q26
Webcast and conference call to be held today at 4:30 pm ET
NEWARK, CALIFORNIA / ACCESS Newswire Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced the selection of PN-477, a potential best-in-class GLP-1, GIP, GCG receptor triple agonist peptide with oral and subcutaneous routes of administration, as a development candidate for the treatment of obesity. The triple agonist PN-477 is designed to offer the optimal combination of total body weight loss, improved gastrointestinal (GI) tolerability and fat to lean mass ratio, with the dosing convenience of a once-daily oral agent and the added optionality of a once-weekly subcutaneous administration.
'We are very pleased to nominate development candidate PN-477, a promising potential best-in class oral GLP-1, GIP, GCG receptor tri-agonist peptide which has demonstrated optimal absolute and relative activity against all three hormone receptors in preclinical testing,' said Dinesh V. Patel, PhD, President and CEO of Protagonist. 'PN-477 is specifically engineered to be orally stable with attention to the relative balance of potencies against the three receptors to potentially leverage their beneficial effects on weight loss and optimal body composition while mitigating their adverse effects. As with our previous drug candidates and late-stage assets, PN-477 is a testament to the power of our peptide technology platform, including the ability to deliver first- and best-in-class targeted oral and injectable peptide therapeutics.'
PN-477 has completed extensive preclinical evaluation including oral and metabolic stability, potency, pharmacokinetics and pharmacodynamics studies, and has demonstrated effects in preclinical models of obesity and glycemic control. PN-477 has shown potent in vitro activity in activating the GLP-1, GIP, and GCG receptors. PN-477 also demonstrated robust preclinical proof-of-concept in various animal studies including the diet induced obesity (DIO) preclinical mouse model, normal dogs, and cynomolgus monkeys. Overall, PN-477 has the right balance of potency, oral and in-vivo stability, and pharmacokinetic properties to enable parallel development both as a once-daily oral (PN-477o) and once-weekly injectable (PN-477sc) treatment options. IND enabling studies of PN-477 are underway and initiation of Phase 1 clinical studies is anticipated in the second quarter of 2026.
'While GLP-1 agonists have dominated the market thus far, there remains a broad opportunity for novel therapeutics with better body weight loss, higher ratio of fat to lean mass loss, tolerability and additional beneficial effects in obesity-related comorbidities. A triple GLP-1, GIP, GCG receptor agonist peptide that offers weight loss on par with the best injectable treatments options, as well as the optionality provided by both oral and injectable routes of administration, would be an important therapeutic breakthrough and represents another potential blockbuster drug opportunity for Protagonist,' added Dr. Patel. 'We look forward to moving PN-477 into first-in human clinical Phase 1 studies in the second quarter of 2026.'
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Monday, June 30 th at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and oral hepcidin.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of PN-477, and the timing of PN-477 clinical development. In some cases, you can identify these statements by forward-looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061 ext. 1
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
26 minutes ago
- USA Today
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announces that it is forging ahead with advancing its lead candidate NV-387 into Phase II clinical drug development. NanoViricides has chosen MPox as the first indication to advance NV-387 into Phase II clinical trials out of the four indications for which the Company has substantial efficacy data in animal studies, namely RSV, Influenza, COVID, and Orthopoxviruses (MPox/Smallpox). The MPox program enables advancing its pipeline towards revenue in the fastest possible manner, the Company believes. The Company intends to advance NV-387 against respiratory infections soon after the Phase II clinical trial of NV-387 for the treatment of MPox infection gets under way. NanoViricides has already added one Clinical trial Site to the MPox Phase II Program. A Phase II Clinical Trial Protocol has been developed with the Principal Investigator at this site in the Democratic Republic of Congo (DRC), and this Protocol is undergoing final refinements. A Clinical Trial Application is in development with many parts having been substantially completed. NanoViricides has engaged a Clinical Research Organization (CRO) to organize and conduct this Phase II clinical trial for the treatment of MPox with NV-387, as previously stated, and this CRO has organized the Clinical Trial Site and is preparing the CTA with the Company's inputs. The manufacture of the drug substance NV-387 is substantially completed at the Company's own facility. The manufacture of the drug product 'NV-387 Oral Gummies' is in progress. MPox as the first indication has several strategic benefits for the Company. Firstly, because of the continuing epidemic in the African Region there is a strong need for the drug and also there is the ability to recruit patients and complete the clinical trial in a timely manner. Additionally, running clinical trials in the African Region is substantially less expensive than clinical trials in USA or Europe that the Company has planned for RSV, a commercially important indication with multi-billion dollar potential market. Secondly, a proof of efficacy in humans of NV-387 against MPox would validate our use of lethal challenge animal models and would establish that our animal model data are predictive of human outcomes. This would have huge implications since our animal model data against every infection we have tested to date has demonstrated NV-387 to be substantially superior to existing drugs, viz. RSV, Influenza, COVID, and of course, MPox/Smallpox. Thirdly, there is a strong financial case for choosing MPox as the indication. This business case has become even stronger with the failure of tecovirimat (Tpoxx) in clinical trial against MPox. Tecovirimat and brincidofovir (Tembexa) are the only two drugs approved by the US FDA for the treatment of Smallpox, a virus of bioterrorism concern. Both of these drugs were approved under the 'FDA Animal Rule', which eliminates the need for demonstration of efficacy in humans. The 'FDA Animal Rule' is applicable for diseases such as Smallpox and others where clinical trials in human patients are not feasible or would be unethical. These FDA approvals have led to the acquisition of these two drugs into the US Strategic National Stockpile (SNS) to the tune of billions of dollars. And now, there is a clear need for replacing these non-performing drugs with a drug that actually works against MPox and Smallpox (see further down below). We believe NV-387 would become the choice for addition to the SNS if our proposed Phase II clinical trial against MPox demonstrates benefits of the NV-387 treatment. The most recent acquisition contracts with BARDA for tecovirimat, which were for drug replenishments, have been valued at over $150million. An initial stocking contract for NV-387 is likely to be substantially larger, as was the case with the initial acquisition of several drugs into the SNS. Brincidofovir failed an early clinical trial against MPox due to liver toxicity. Tecovirimat failed a recent clinical trial against MPox since it demonstrated no superiority in efficacy over the standard of care. Importantly, both of these drug candidates are small chemicals that the viruses can readily escape by mutations. Smallpox, if it ever becomes fielded as a bio-terrorism agent, is unlikely to be in the 'original' form of the virus, and could be explicitly manipulated to breed resistance to such small chemical drugs by onerous entities. Of note, MPox is in the same family as the Smallpox virus; MPox causes a much weaker form of disease than the Smallpox virus. Thus there is a strong case for HHS to support NV-387 drug development for Bioterrorism Readiness. The 'NV-387 Oral Gummies' drug product is a soft solid formulation that is designed to stick in the oral cavity and dissolve naturally over time, with no solid object (pill or capsule) swallowing necessary. This is important for MPox because MPox causes lesions on mucosal surfaces that make swallowing painful and difficult. MPox is primarily known for the explicit characteristic painful rash on the external skin, but it is a significantly more severe disease than just a skin rash. The MPox virus circulating in DRC and neighboring regions is of Clade 1a and Clade 1b subtypes, with the latter predominant. Clade 1b is more transmissible of the two, which is why it has resulted in a sustained epidemic. The MPox Clade 1a case fatality rate (CFR) is about 3%-11% whereas the CFR for Clade 1b is about 1%. The MPox Clade 2b is the virus causing continuing cases in the Western world, which causes a much less severe disease than Clade 1a/1b and has a very low CFR, according to CDC. Sporadic cases of Clade 1 in the Western world continue to occur. Four separate travel-related MPox Clade 1 cases reported in the USA that did not result in any further spread, since November 2024, according to the CDC ( ). Clearly, the threat of MPox Clade 1 causing a potential epidemic in the USA cannot be ignored, and readiness with a drug that works against the same is important to achieve. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( ) is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Contact: NanoViricides, Inc. info@ Public Relations Contact: ir@ SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire
CNN
32 minutes ago
- CNN
Major insurance changes are coming to GLP-1 drugs for weight loss. Here's how that could affect patients
Prescription drugs Food & health Chronic diseasesFacebookTweetLink Follow Last week, Tara Eacobacci had an appointment with her doctor that was devoted exclusively to the topic of health insurance. A major change to her prescription benefits meant the medication she was using to manage her weight – a treatment that had taken years of trial and error to get right – would no longer be covered by insurance. 'I'm completely outraged,' Eacobacci said. 'It's not only causing me stress, but it is making me angry.' Starting Tuesday, CVS Caremark – a major pharmacy benefit manager that serves as a middleman for health insurers, large employers and other payers to manage their prescription drug plans – will stop covering Eli Lilly's Zepbound, a blockbuster GLP-1 drug that has been approved by the US Food and Drug Administration since November 2023 for chronic weight management in adults with obesity or who are overweight. 'This change is happening because there's another covered medication that's safe and effective for your condition and may cost less,' CVS Caremark said in a letter sent in May to its patients using Zepbound. 'Please keep in mind, if you refill your current medication on or after 7/1/2025, you'll need to pay the full cost.' Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark, along with a few other medications that are generally less effective. CVS says the decision to cover Wegovy and exclude Zepbound is 'forcing the drug manufacturers to compete with one another' and will encourage both Eli Lilly and Novo Nordisk to lower prices for their products in the US. 'The egregiously high list prices set by drug manufacturers of GLP-1s for weight loss are the single biggest barrier to patient access,' CVS Health said in a statement. 'Our formulary strategy maintains clinically appropriate coverage while using competition to drive lower costs.' But pharmacy benefit managers – of which CVS Caremark is one of the largest – have faced scrutiny for their role in rising drug costs in the US. When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people managing obesity as a chronic disease. 'Largely across society, we don't accept obesity as a long-term chronic disease, and we're still looking for quick fixes and quick solutions where that's not the reality of the biology and disease process. The mindsets have not caught up with the science yet,' said Dr. Tracy Zvenyach, director of policy strategy and alliances at the Obesity Action Coalition, a nonprofit advocacy group. 'If decision-makers do not understand obesity to be a long-term chronic disease, that's when we see these exclusionary policies or these very, very cumbersome utilization management practices that really just set up one barrier after another to prevent people from getting the care that they need. It's unacceptable. We don't do that with other chronic diseases.' It takes time to develop a treatment plan with GLP-1 drugs that works with each individual patient, said Dr. Jody Dushay, an endocrinologist at Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School. Some people might have an allergic reaction at the injection site for one medication or have worse side effects – such as severe constipation, nausea or stomach pain – with one than another. Adapting to a change in medication will often interrupt a patient's weight-loss trajectory, she said, and the trial-and-error could create a lot of waste for medications that were in shortage not long ago. 'As soon as these announcements [about insurance coverage changes] come out, I get flooded with messages from patients,' she said. 'It's very stressful for patients who have been doing really well, who are having good tolerance and feel like they have hit their stride in terms of medication, nutrition and exercise. Everything is heading in the right direction, and then having to switch can be very disruptive.' When Dushay is looking through a patient's medical chart, she says, her stomach churns when she sees the little box that indicates their insurance information. 'In this field of weight management, that little teeny part of the chart dictates so much of their care. For me, it's unprecedented in terms of how much insurance matters for the clinical care that I'm providing and the choices that I have,' she said. And discussing strategies to manage insurance-mandated changes in treatment infringes on clinical care. 'There is barely time to ask the patient how they are feeling, about side effects and weight loss and general health updates,' Dushay said. 'There is a loss of time for patient care and a huge increase in time burden outside the visit for doctors and pharmacists.' Another major insurance change coming next year will affect another large swath of Dushay's patients: In January, BCBS Massachusetts will be excluding all GLP-1s from coverage for treatment of obesity, reserving coverage for these drugs only when indicated to treat type 2 diabetes. 'The nation is facing an obesity crisis. That's why we work hard to support our members achieve a healthy weight by improving access to nutritious food, physical activity programs, and quality clinical care when needed,' David Merritt, senior vice president of external affairs for the Blue Cross Blue Shield Association, said in a statement. 'We share the enthusiasm for the real weight loss success experienced by the countless patients taking GLP-1s. As with any new medication, there is more to learn to ensure patients are set up for success. Last year, we published a study that found roughly 60% of people do not stay on GLP-1s long enough to see meaningful weight loss. While adherence is improving, we need more data to ensure these costly medications deliver long-term value for patients and the health care system.' Zepbound and Wegovy are both effective at treating obesity and approved by the FDA to do so, but there are differences. Studies have found that people who used tirzepatide injections such as Zepbound lost more weight and were more likely to reach specific weight loss targets than those using semaglutide medications such as Wegovy. The two drugs have a different set of broader indications, with Zepbound also approved to treat sleep apnea in people with obesity, for example. Side effects can vary, too, sometimes making one medication more tolerable than the another. People who have had success with Zepbound may be able to file for an exception after the insurance coverage changes, but CVS Caremark has limited options to proactively plan for the change, leaving many patients angry and concerned about their health and well-being. For Eacobacci, the insurance changes and the sentiment behind them are enraging – and based in prejudice. CVS Caremark had required that she try multiple alternate treatments and prove that they didn't work before she was approved for Zepbound this year. When she was on Wegovy, she said, her A1C glucose levels started to rise close to prediabetic levels despite consistent diet and exercise habits. This all changed once she started Zepbound. 'I feel better. I'm not as bloated. My movement is definitely different. I fit into my clothes, but I also feel validated – because all of these years, doctors say to you, 'Oh, you can't eat all that cake and candy,' and they don't believe that you're not,' Eacobacci said. 'The medication actually validated some of this. Like, 'hey, I do need support. I can't do this on my own as much as I'm trying.' ' Medication changes could have unnecessarily dangerous impacts on physical health – Eacobacci said she gained 10 pounds and saw her A1C levels spike in just one month without the medication – as well as mental health. 'Weight stigma and bias has affected us nationwide,' said Eacobacci, who is worried about many people she knows who have felt depressed after the hearing the news about changes in insurance coverage. 'You made me jump through hoops. I got the prior authorization you required for me, and now you're – mid-year – taking it away from me is so impactful that it should be illegal.' Although coverage exceptions may be an option, the appeals process takes time. 'It gets really, really frustrating to have to justify what I want to do all the time just because of money,' Dushay said. For people who do lose coverage of Zepbound, drugmaker Eli Lilly has expanded access through LillyDirect, a company platform that helps coordinate telehealth services and fill prescriptions for patients who pay out-of-pocket. Single-dose vials are available for $499 per month through the LillyDirect Zepbound Self Pay Journey Program, with the highest doses available beginning July 7. 'We're confident in Zepbound's performance and remain committed to ensuring patients have access to the treatment they need,' Lilly said in a statement.
Fast Company
39 minutes ago
- Fast Company
This entrepreneur made billions on crypto. His next frontier is outer space
Perched on a dusty high desert plain about 100 miles north of downtown Los Angeles, the Mojave Air and Space Port looks more like a final destination for aerospace experiments than a stepping stone to the stars. A field with dozens of decommissioned commercial jetliners bakes in the early morning sun–it'll eventually hit 110 degrees around noon–and the small shacks set between dusty roads and cracked pavement look mostly empty. But drive past cracked airstrips and barbed wire gates, and—with the right security clearance—you may be able to walk up and touch the exterior of the next orbital space station: a 2-ton cylindrical aluminum module built by the startup Vast. Called Haven-1, it currently hangs from a 50-foot-tall steel scaffold while it undergoes extreme pressure testing, one of many complicated engineering milestones it needs to hit before its planned launch in May 2026. Before engineers can install the module's instrumentation, electronics, and life-support systems, they need to repeatedly pressurize the structure to 2.4 times Earth's atmosphere to test its workmanship. Massive hoses hooked up to a trio of multistory liquid nitrogen tankers inflate the station—an isogrid metal shell that resembles a waffle cone—with nitrogen gas, like a kid's birthday balloon. Observers need to stand at least 236 feet away in case bolts or brackets burst. During a visit in May, workers were welding and reinforcing the steel scaffold to make sure the structure can withstand a grueling and aggressive series of stress tests that will see the cabin inflated and deflated 200 times in a row. Vast is racing against the clock to launch the world's first commercial space station—independently, in-house, and in record time. It's an audacious effort, made possible by the retirement of an icon: the International Space Station, a fixture of childhood imaginations and of humanity's exploration of space since its first section was launched in 1998. It's now set to be decommissioned in 2030, via a guided crash into the Pacific Ocean, and Vast wants to replace it. The extended deadline for Fast Company's Next Big Things in Tech Awards is this Friday, June 27, at 11:59 p.m. PT. Apply today.
